The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma

By
Justin.choi
-
0
241
Orthotopic and ectopic hepatocellular carcinoma models were constructed by implanting Hepa1-6 cells at different body sites of mice. Immune agents were administrated via three ways, including intratumoral injection into one site of the tumor, intraperitoneal injection, and subcutaneous injection.
[Journal of Hepatocellular Carcinoma]
Zhou, Z., Lin, L., An, Y., Zhan, M., Chen, Y., Cai, M., Zhu, X., Lu, L., & Zhu, K. (2021). <p>The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma</p>. Journal of Hepatocellular Carcinoma, 8, 529–543. https://doi.org/10.2147/JHC.S301375 Cite
Abstract